An observational study in Myositis, Myasthaenia Gravis and Neuropathy, sponsored by Central Hospital, Nancy, France. Not yet recruiting at 1 site in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-02-18.
Sponsored by Central Hospital, Nancy, France · Observational
MEK inhibitors (trametinib, cobimetinib, selumetinib or binimetinib) have been used since 2016 to treat metastatic melanoma, by targeting the MAPK pathway Neuromuscular complications (neuropathy, myasthenia or myositis) have been reported in patients treated with MEK inhibitors.
With the growing use of these new oncology therapies, neurologists, oncologists and other clinicians are likely to be increasingly confronted with MEK inhibitor-induced neuropathy, myasthenia or myositis.
Yet, so far, these complications have only been documented in a few single case reports.
Our aim was to characterize the neuromuscular complications associated with MEK inhibitors used either alone or in combination.
242 studies on the registry are indexed under Myositis; 103 are open to participants now.
This study's planned enrollment of 5 is below the median of 226 across 72 observational studies indexed under Myositis.
Browse Myositis studies →Central Hospital, Nancy, France is the lead sponsor of 778 studies on the registry; 183 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Patients with neuromuscular complications treated with MEK inhibitors at a Neuromuscular Reference Center in France
Exclusion Criteria:
no intervention
Type of neuromuscular complications
Time frame: up to 8 years
Time to onset after introduction of MEK inhibitors
Time frame: up to 8 years
Severity of neuromuscular complications
Time frame: up to 8 years
Progression with or without treatment
Time frame: up to 8 years
Reintroduction of MEK inhibitors
Time frame: up to 8 years
This study is not yet recruiting, as verified in Dec 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Central Hospital, Nancy, France